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Abstract 
 
Background: Cardiovascular disease is the most common cause of mortality and 
morbidity in the United States as well as many other nations. Recent evidence 
supports an association of vitamin D deficiency with hypertension, peripheral 
vascular disease, diabetes mellitus, metabolic syndrome, coronary artery disease, and 
heart failure. We wished to study the association of vitamin D deficiency in a cohort 
of patients followed by a large cardiovascular practice at an academic medical 
institution, as well as the association of vitamin D replacement with improvement in 
cardiovascular outcomes. 
Methods: Serum vitamin D measurements for 5 years and 8 months (1/1/2004 to 
10/8/2009) from The University of Kansas Hospital were obtained. These values were 
matched to patient demographic, physiologic and disease state variables from the 
cardiovascular database. Serum vitamin D levels were analyzed as a continuous 
variable and as normal (>30ng/ml) or deficient. Descriptive statistics, univariate 
analysis, multivariate analysis, survival analysis, and Cox proportional hazard 
modeling were performed. 
Results: 10,899 patients were available for analysis. Mean age was 58.3 +/- 14.9 
years. There were 7758 (71%) women and 3141 (29%) men. Mean weight was 185.7 
+/-52.0 lbs and BMI was 29.9 +/- 7.7 Ejection fraction was 57.2 +/- 10.4%. Mean 
vitamin D was 24.1 +/- 13.6 ng/ml.. 3294 (29.7%) subjects were in normal range 
(≥30ng/ml) and 7665 (70.3%) were deficient (<30ng/ml). Vitamin D deficiency was 
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found to be associated with several cardiovascular disease states including 
hypertension, coronary artery disease and cardiomyopathy; as well as diabetes and 
death (all P’s < .05). Logistic regression analysis found vitamin D deficiency to be a 
strong predictor of death (OR 2.64, CI 1.901-3.662, P < .0001). This association 
persisted with other clinical variables such as, BMI, gender, and ejection fraction 
added to the model and was confirmed by survival as well as hazard function 
analysis. Vitamin D replacement conferred substantial survival benefit (OR for death 
0.39, CI 0.277-0.534, P < .0001) and was particularly beneficial in vitamin D 
deficient patients. The interaction of vitamin D deficiency and supplementation was 
analyzed as well as the association of vitamin D deficiency and certain coronary 
artery disease risk factors. 
Conclusions: Vitamin D deficiency is a significant risk factor for several 
cardiovascular disease states and is a significant independent predictor of reduced 
survival. Vitamin D supplementation improves survival with greater benefit in 
deficient patients. Prospective randomized trials of vitamin D supplementation in 
patients with cardiovascular diseases are warranted, as well as consideration for 
increased supplementation in the general public. 
 
Keywords: Vitamin D, Cardiovascular Diseases, Risk Factors 
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Introduction  
Background 
Cardiovascular disease is the most common cause of mortality and morbidity in the 
United States as well as many other nations. Recent evidence supports an association 
of Vitamin D deficiency with hypertension, peripheral vascular disease, diabetes 
mellitus, metabolic syndrome, coronary artery disease, and heart failure. It is 
emerging as a major and widespread cardiovascular risk factor. 
 Vitamin D Metabolism 
Vitamin D belongs to a group of secosteroid molecules that are traditionally 
associated with bone and calcium metabolism. Although 5 forms of vitamin D 
(designated D1 to D5) are known, vitamin D2 and D3 are the most studied forms 
(Table 1). Ergocalciferol or vitamin D2 is principally synthesized in plants and  
Table 1 Forms of Vitamin D 
 
Class Chemical Composition Source 
Vitamin D1 Combination of  Ergocalciferol 
and Lumisterol 
 
Vitamin D2 Ergocalciferol-made from 
Ergosterol or pre-Vitamin D2 
Made by invertebrates, fungus 
and plants in response to UV 
irradiation; Not made by 
vertebrates 
Vitamin D3 Cholecalciferol-made from 7-
Dehydrocholesterol or pre-
Vitamin D3 
Made in the skin as a response 
to UVB reacting with 7-
Dehydrocholesterol.  
Vitamin D4 Dihydroergocalciferol-Vitamin 
D2 without 22,23 double bond 
Ineffective form of Vitamin D 
Vitamin D5 Sitocalciferol-made from 7-
Dehydrositosterol 
May have anti-tumor properties 
8 
 
Figure 1 Metabolic pathways of Vitamin D 
 
invertebrates and is consumed in the human diet and as supplements or fortified 
products. Cholecalciferol or vitamin D3 is mainly of vertebrate animal origin and 
commonly consumed from oily fish. Cholecalciferol is also synthesized in the skin 
after exposure of 7-dehydrocholesterol to solar ultraviolet radiation (Figure 1). 
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Approximately 80-90% of vitamin D comes from cutaneous conversion, with only 
10-20% from dietary sources. Both endogenous and consumed Vitamin D are stored 
in fat tissues and released into the circulation. Vitamin D is bound to a circulating 
glycoprotein called vitamin D binding protein (DBP). The liver converts Vitamin D 
to 25 [OH] Vitamin D which is largely inert. In a rate limiting step, the kidneys 
convert 25 [OH] Vitamin D to its active form 1, 25 [OH]2 vitamin D, which is bound 
to specific receptors (VDR) at several sites in the body (Figure 2). Serum levels of 
1,25dihydroxyvitamin D are primarily determined by renal production, which is 
closely associated with calcium homeostasis and is up regulated by parathyroid 
hormone, which increases in response to low serum calcium levels. 
Figure 2 Vitamin D Structure, Transport and Receptor Mechanics 
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Cholecalciferol (D3) 
 
 
Ergocalciferol (D2) 
In humans, VDR is an intranuclear class II steroid hormone receptor. The conjugated 
Vitamin D with its receptor forms a heterodimer complex with retinoid X receptor. 
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Together with several other factors and an activator, this complex attaches to Vitamin 
D responsive elements on DNA and alters gene expression1.  VDR are found in 
enterocytes, osteoblasts, parathyroid cells, and the distal renal tubule cells. Vitamin D 
increases calcium absorption from gut and renal tubular cells and suppresses 
parathyroid hormone. It acts on osteoblasts and increases bone mineral density. 
Recent studies have revealed that VDRs also have a significant presence in the liver, 
immune system, skeletal system, and cardiac muscle2.  Proposed cardiovascular and 
other physiologic effects are shown in Figure 3. 
Figure 3 Vitamin D absorption and effects 
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Laboratory Measures of Vitamin D 
Serum 25[OH] Vitamin D is the major circulating metabolite of vitamin D and 
reflects vitamin D input from cutaneous synthesis and dietary intake. Although 
1,25[OH]2 vitamin D is the biologically active form of vitamin D, serum 25[OH] 
vitamin D is regarded as the best indicator of vitamin D status in individuals without 
kidney disease. In contrast, 1, 25[OH]2 vitamin D levels can be normal or even 
elevated in patients with vitamin D deficiency. 
Multiple assay methods are available for measurement of serum levels of vitamin D, 
detailed discussion of which is beyond the scope of this paper. Variation in assay 
sensitivity makes comparison of vitamin D levels from different studies problematic.  
Normal ranges for serum 25[OH] vitamin D concentrations are not well established. 
In a large meta-analysis, serum 25[OH] vitamin D concentrations and multiple end 
points were compared to establish optimal serum levels. The most beneficial serum 
concentrations of 25[OH] vitamin D were observed at levels >30 ng/mL (>75 
nmol/L) with optimal levels between 36 – 40 ng/mL (90 - 100 nmol/L). Many experts 
and clinical laboratories define vitamin D insufficiency as  25[OH]D levels between  
21 to 29 ng/ml while levels less than 20 ng/ml (50 nmol/l) indicate vitamin D 
deficiency 3. In many patients, current daily recommended doses of 200 to 600 IU 
have not been shown to reach beneficial serum concentrations 4. 
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Vitamin D Epidemiology 
Worldwide, most humans typically expose 5% or less of their skin to infrequent 
periods of unshielded sunlight, a behavior which commonly leads to vitamin D 
deficiency. This is far less solar exposure than that experienced in most historical 
human cultures and free living primates. It is estimated that 30% to 50% of the 
general population suffer from vitamin D deficiency. In one study, 36% of young 
healthy free-living adults in the USA aged 18 to 29 years had vitamin D deficiency at 
the end of winter 5. In elderly and institutionalized patients, the prevalence of vitamin 
D deficiency is higher 6. The Third National Health and Nutrition Examination 
Survey (NHANES III) reported the prevalence of vitamin D deficiency in the U.S. to 
be between 25% and 57% of adults 7. The risk factors for vitamin D deficiency 
include advanced age, dark skin color, institutionalized or homebound status, 
increased distance from the equator (Figure 4), winter season, clothing, sunscreen, air 
pollution, smoking, obesity, malabsorption, renal disease, liver disease, and 
medications 3.  
Recommended Daily Intake and Toxicity: 
The present recommended daily allowance is 400 IU daily. However as noted above, 
intake in this range may not be adequate to avoid deficiency in many people.4 The 
Food and Nutrition Board has established the tolerable upper intake level for vitamin 
D at 2000 IU/day but this has been questioned 8.  It is estimated that African 
Americans with low sun-exposure need an intake of 2100-3100 IU/d of vitamin D  
14 
 
Figure 4 Area of the United States above the 37th parallel at risk of reduced sunlight 
exposure. 
 
 
orally throughout the year to achieve a serum 25-[OH] vitamin D concentration of 
≥30mg/mL (75 nmol/L) 9. Total-body sun exposure easily provides the equivalent of 
250 µg (10,000 IU) vitamin D/day, suggesting that this is a physiologic limit 10.  
Hypervitaminosis D is described as rare and typically results from massive doses of 
oral supplementation over prolonged time and presents with symptoms related to 
hypercalcemia which includes anorexia, nausea, and vomiting followed by polyuria, 
polydipsia, weakness, nervousness, pruritus, and eventually even renal failure. Recent 
evidence suggests that vitamin D is well tolerated over a large intake range 8. A 
healthy female tolerated an oral dose of 150,000 IU daily for 28 years without any 
toxicity 11.  Other case reports describe 2 patients who had self-prescribed supra-
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therapeutic doses of vitamin D and had serum concentrations of 260 nmol/L and 1126 
nmol/L for months to years without significant hypercalcemia or other side effects 12. 
Present Study Outline 
The goals of this study were to study the association of vitamin D levels with 
coronary artery disease, hypertension, diabetes and other disease processes, to the  
assess the relationship of vitamin D levels to survival, and to evaluate the association 
of vitamin D supplementation with outcomes. The study population was a 
retrospective sampling from a cohort of patients followed by a large cardiology 
practice at an academic medical institution, the University of Kansas Hospital and 
Medical Center in Kansas City, Kansas.  We defined the optimal concentration of 
25[OH] vitamin D as at least 30 ng/ml and vitamin D deficiency as a 25[OH]D level 
of <30 ng/ml.  For this study serum vitamin D levels were analyzed both as a 
continuous variable and as normal (>30ng/ml) or deficient.  
The 1st set of hypotheses were: null: vitamin D levels are not associated with 
cardiovascular outcomes and survival; and alternative: vitamin D levels are associated 
with cardiovascular outcomes and survival at the .05 level of significance. 
The 2nd set of hypotheses were: null: vitamin D supplementation is not associated 
with improved cardiovascular outcomes and survival; and alternative: vitamin D 
supplementation is associated with improved cardiovascular outcomes and survival. 
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Methods 
Serum vitamin D measurements for 5 years and 8 months (1/1/2004 to 10/8/2009) 
from the University of Kansas Hospital were obtained.  Our laboratory uses the 
DiaSorin® (Stillwater, MN) chemiluminescence immunoassay method to 
measure total serum vitamin D (both 25 hydroxy D2 and D3 forms of vitamin D.) The 
laboratory assay did not change over this period. These values were matched to 
patient demographic, physiologic and disease state variables from the cardiovascular 
database at the medical center and provided in de-identified format. Diagnoses were 
derived from the patient problem list in the patients’ electronic medical record based 
on International Classification of Diseases, 9th Revision (ICD-9) codes. Death was 
determined from the Social Security Death Index. 
A total of 24,895 samples were tested in the University of Kansas Hospital 
laboratory. There were 14,261 unique patients. The lowest recorded value for patients 
with multiple measurements was used for analysis. Database query yielded 
information on 11,017 matching patients. After excluding patients who were less than 
18 years of age, 10,899 patients were available for analysis. This data was then 
“cleaned” and formatted to allow statistical analysis in Microsoft Excel 2007. The 
data was then imported into SAS 9.1.3 for statistical analysis and modeling. 
Descriptive statistics, univariate analysis [(unpaired t tests for continuous variables, 
chi square analysis for categorical variables, logistic regression for odds ratios (OR) 
and confidence intervals (CI)], multivariate analysis using logistic regression for OR 
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and CI, survival analysis, and Cox proportional hazard modeling were performed.  A 
.05 level of significance was used throughout. 
The SAS syntax developed for the analysis is provided in Appendix 1. Sample 
routines for each type of analysis are provided. Multiple variations of these routines 
were performed to assess various models and variable combinations. 
Results 
 Demographics and Univariate Analyses 
General descriptive statistics include mean age 58.3 +/- 14.9 years with normal 
distribution (Figure 5). There were 7758 (71%) women and 3141 (29%) men. Mean 
weight was 185.7 +/-52.0 lbs and body mass index (BMI) was 29.9 +/- 7.7 (Figure 6). 
Both weight and BMI distributions were near normal with right skew. Ejection 
fraction (by echocardiogram) was 57 +/- 10% with left skew. 
Descriptive statistics for vitamin D values included mean 24.1 +/- 13.6 ng/ml and 
median 22.5 with right skew (Figure 7). 3234 (29.7%) subjects were in normal range 
(≥30ng/ml) and 7665 (70.3%) were deficient (<30ng/ml).  
Baseline characteristics for the subjects with and without vitamin D deficiency are 
shown in Table 2.  
Univariate analysis was then performed with the odds ratios of an event if the subject 
was vitamin D deficient vs. not (as a dichotomous predictor variable) presented in 
Table 3. Vitamin D deficiency was significantly associated with several  
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Figure 5 Age distribution of subjects 
 
Figure 6 BMI distribution of subjects 
 
cardiovascular disease states including coronary artery disease, atrial fibrillation, 
diabetes, cardiomyopathy, and hypertension, as well as death. All are positive 
associations other than that for atrial fibrillation. 
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Figure 7. Vitamin D distribution of subjects 
 
Table 2 Baseline Characteristics ( ) = % 
 
Variable Vitamin D Deficient 
n =7665 
Not Vitamin D Deficient 
n=3234 
p 
Atrial fibrillation 201 (6) 398 (5) .03 
Aspirin use 997 (31) 2254 (29) NS 
Angiotension converting enzyme 
inhibitor use 
725 (22) 2089 (27) <.0001 
Age 60 +/- 15 58 +/- 15 <.0001 
BMI 28 +/- 7 31 +/- 8 <.0001 
Coronary artery disease 306 (9) 830 (11) .03 
Cardiomyopathy 95 (3) 288 (4) .03 
Cholesterol level 166 +/- 43 171 +/- 54 .02 
Creatinine level 1.38 +/- 6.29 1.58 +/- 2.98 NS 
Ejection fraction 58 +/- 10 57 +/- 10 NS 
Diabetes 294 (9) 1436 (19) <.0001 
Gender (female) 2503 (77) 5255 (69) <.0001 
Death 43 (1) 293 (4) <.0001 
HDL cholesterol level 52 +/- 18 47 +/- 16 <.0001 
Hypertension 938 (29) 2795 (36) <.0001 
LDL level 92 +/- 33 97 +/- 39 .002 
Statin use 1098 (34) 2611 (34) NS 
Triglyceride level 115 +/- 80 140 +/- 126 <.0001 
Valvular heart disease 181 (6) 487 (6) NS 
Vitamin D level 40 +/- 11 17 +/- 7 <.0001 
Vitamin D supplement use 689 (21) 2423 (32) <.0001 
Vitamin supplement (any) 1097 (34) 2992 (39) <.0001 
   NS = not significant at 0.05 level 
Vitamin D levels (ng/ml) 
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Table 3 Univariate Analysis: Odds Ratio of Event if Vitamin D Deficient  
 
Event  OR  CI  P  
Death  2.95  2.135-4.073  <.001  
CAD  1.16  1.012-1.334  .03  
Atrial Fibrillation  0.83  0.693-0.984  .03  
Diabetes  2.31  2.018-2.633  <.001  
Cardiomyopathy  1.29  1.019-1.633  .03  
Hypertension  1.40  1.285-1.536  <.0001  
 
Vitamin D Deficiency: Logistic Regression 
Logistic regression using death as the dependent variable and the variables above as 
well as vitamin D deficiency yielded an overall model P < .0001 with results in Table 
4. Vitamin D deficiency was a strong predictor of death along with coronary artery 
disease, diabetes, cardiomyopathy, and hypertension. 
Table 4 Logistic regression for death as dependent variable 
Predictor  OR  CI  P  
CAD  2.71 2.062-3.573  <.0001  
Vitamin D deficiency  2.64  1.901-3.662  <.0001  
Diabetes  1.45  1.114-1.891  .006  
Cardiomyopathy  3.29  2.359-4.596  <.0001  
Hypertension  1.53  1.183-1.969  .001  
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Stepwise selection was performed with all 5 variables included in model, with entry 
criteria = .10, and removal criteria = .15. All variables were retained in the model 
with c statistic = .734, suggesting acceptable goodness of fit for the model. 
Logistic regression for death as the outcome variable with vitamin D level as a 
continuous predictor variable resulted in an odds ratio of .95 (CI .944-964), P < .0001 
for the model. Higher vitamin D levels are protective. In a multivariate model as 
above, the vitamin D level as a continuous variable OR was .96 with the OR for the 
other variables and overall model significance similar as for the model with Vitamin 
D as a categorical variable. Stepwise selection with all 5 variables included in the 
model and similar entry and removal criteria resulted in all variables being retained in 
the model and a c statistic = .758. 
Logistic regression for death was performed with additional clinical variables added 
(Table 5). The overall model was predictive with P < .0001 and with vitamin D 
remaining a very strong predictor variable. By correlation analysis age and coronary 
artery disease appeared to be significantly correlated. When age was removed from 
the model, coronary artery disease became a significant predictor of death (OR 1.45, 
CI 1.056-1.986, P = .02). 
Stepwise selection of the expanded model resulted in hypertension, coronary artery 
disease and creatinine dropping out. Vitamin D deficiency was the strongest predictor 
with OR 2.36 (CI 1.583-3.511), P < .0001. c = .709. 
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Table 5 Logistic regression for death with additional clinical variables added  
Event OR CI P 
Vitamin D deficiency 2.42 1.622-3.612 <.0001 
CAD 1.28 0.926-1.769 NS 
Diabetes 1.45 1.051-1.994 .02 
Cardiomyopathy 1.52 1.018-2.283 .04 
Hypertension 0.81 0.585-1.110 NS 
Age 1.02 1.008-1.033 .001 
BMI 0.96 0.935-0.980 .0003 
Ejection Fraction 0.98 0.970-0.994 .003 
Creatinine 1.01 0.986-1.039 NS 
Gender (female) .0.63 0.464-0.844 .002 
  
Vitamin D Deficiency: Survival Analysis and Cox Proportional Hazards 
Modeling 
Survival was then studied. Survival method 1 examined lifelong survival calculated 
as survival time = date of death – date of birth if the patient died, otherwise survival = 
end of study (October 9, 2009) – date of birth. This survival estimate may be biased 
because it extends survival observation retrospectively before the period of data 
analysis. However it was felt reasonable to analyze this lifelong survival interval in 
relation to a contemporary vitamin D measurement. The correlation of the results 
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with those obtained with the 2nd survival method below may support the importance 
of vitamin D in long term outcomes. 
Survival curves are presented in Figure 8 with consistently better survival for those 
patients not vitamin D deficient (P < .0001 for homogeneity of strata). 
Figure 8 Survival Curve Method 1 
 
Survival method 2 calculated survival as survival2 = Date of death – date of 
collection, otherwise Survival 2 = End of study – date of collection. This may be a 
more appropriate means of assessing survival relative to the measurement of vitamin 
D level and clinical parameters. The survival curve for method 2 is given in Figure 9 
(P < .0001 for homogeneity of strata). 
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Figure 9 Survival Curve Method 2 
 
Expanded Scale shown below: 
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Hazard ratios using the Cox proportional hazards model were then calculated with 
vitamin D deficiency as a dichotomous variable with results shown in Table 6 for the 
disease state variables, using survival method 1 (P < .0001 for both vitamin D 
deficiency and overall model with vitamin D deficiency being the strongest individual 
predictor). Hazard function analysis with additional predictive variables (age, BMI, 
EF, gender) was then performed with overall P < .0001 and vitamin D remaining a 
significant independent predictor. Vitamin D deficiency remained the variable with 
the highest OR (2.52).  Hazard function analysis was also performed using survival 
method 2 and vitamin D deficiency as a dichotomous variable (Table 7) with the 
overall model being highly predictive as well as vitamin D as an independent 
predictive variable (P < .0001 for both). Similar results were found in the expanded 
clinical model when hazard ratios were generated using survival method 2. Therefore, 
survival whether assessed by a traditional method from study onset (method 2) or by 
extension to birth (method 1) shows that vitamin D deficiency is associated with 
decreased survival by the proportional hazards method. 
Table 7 Hazard Ratios for Death with Vitamin D deficiency (dichotomous)-Survival 
Method 2 
Predictor  Hazard Ratio  CI  P  
CAD  2.617  2.006-3.414  <.0001  
Diabetes  1.497  1.162-1.929  .0018  
Cardiomyopathy  2.766  2.033-3.764  <.0001  
Hypertension  1.586  1.236-2.036  .0003  
Vitamin D deficiency  2.174  1.574-3.003  <.0001  
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Vitamin D Supplementation: Relationship and Interaction with Vitamin 
D Deficiency 
For the next portion of the study, the impact of vitamin D supplementation was 
studied. Data was coded as either 1 for supplement use recorded in the electronic 
medical record or 0 if no use was documented. Use was more common in vitamin D 
deficient patients, with 31.6% of deficient patients receiving supplements vs. 21.3% 
of patients with normal vitamin D values receiving supplements (OR 1.71, P<.0001). 
Death vs. vitamin D deficiency was stratified by vitamin D supplementation. With 
supplementation, the OR for death = 1.46 (CI 0.760-2.799) (P=NS)). Without 
supplementation the OR for death = 3.72 (CI 2.563-5.396) (P<.0001). Controlling for 
vitamin D replacement, the common OR = 3.07 (CI 2.222-4.228) (P<.0001) (by 
Cochran-Mantel-Haensel analysis). The Breslow-Day test for homogeneity of OR = 
0.01.  
To further study this interaction, the Cox proportional hazards model was then run 
with only the variables for vitamin D deficiency and supplementation included. The 
hazard ratio using survival method 1 for deficiency was 3.70 (CI 2.680-5.097) and for 
supplementation was 0.51 (CI 0.389-0.665)(both P’s < .0001). When the model was 
run stratifying vitamin D deficiency by supplementation, the hazard ratio was 3.69 
(CI 2.674-5.085), P < .0001.  Using survival method 2 the hazard ratio for deficiency 
was 2.60 (CI 1.864-3.540)(P < .0001). When stratified by supplementation the hazard 
ratio for deficiency as 2.60 (CI 1.884-3.578) using survival method 2. 
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Next the possible interaction between vitamin D deficiency (as a dichotomous 
variable) and supplementation was studied by creating an interaction variable for 
vitamin D deficiency*supplementation (interactionA). When this interaction term was 
added to a hazard model with vitamin D deficiency and supplementation, the overall 
model P remained significant as did that for vitamin D deficiency (both P’s < .0001, 
hazard ratio for deficiency 4.515). The interaction term was significant at P = .0036 
with a hazard ratio of 0.330, while vitamin D supplementation was no longer a 
significant predictor. The model was significant by both Wald statistic and by 
likelihood ratio test (P < .0001). Proportionality testing was highly significant (P = 
.0036), suggesting an important interaction. A second non-time dependent interaction 
variable (interactionB) was developed as the product of the continuous value of the 
vitamin D measurement and the dichotomous value of vitamin D replacement as 
described below in the final model section.  This interaction variable yielded a highly 
significant outcome (P<.0001) by proportionality testing, suggesting that the vitamin 
D deficiency-supplementation interaction is indeed important. 
 Vitamin D Supplementation: Logistic Regression and Cox Proportional 
Hazards Modeling 
The analyses for death by logistic regression and by Cox proportional hazard models 
were then repeated both with the limited, disease related variable sets as well as with 
the expanded variable models, either adding either the interaction term A or B and 
retaining vitamin D supplementation as a variable, or with the interaction term 
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included and vitamin D supplementation removed.  This was done using both survival 
methods 1and 2 with similar results. In all cases, both with full model testing and by 
stepwise selection (using inclusion criteria of .10 and removal criteria of .15), vitamin 
D supplementation alone became a nonsignificant predictor while the interaction term 
was highly significant. In general the level of significance and association hazard 
ratios for the interaction term were similar whether the interaction term was included 
alone or with vitamin D supplementation also included. These levels of significance 
and hazard ratios were also similar for models containing vitamin D supplementation 
alone with no interaction term. Table 8 gives an example of these relationships, with 
basic models of vitamin D deficiency, supplementation, and the interaction term.  
Table 8 Example of Relative Contribution of Interaction Term of Vitamin D 
Deficiency*Supplementation in Hazards Model 
Model Variables Hazard Ratio P 
1 Vitamin D Deficiency 3.37 (2.680-5.097) <.0001 
 Vitamin D Supplement 0.51(0.389-0.665) <.0001 
2 Vitamin D Deficiency 4.52 (3.121-6.534) <.0001 
 Vitamin D Supplement 1.35(0.682-2.684) .3877 
 Interaction Term 0.33 (0.157-0.696) .0036 
3 Vitamin D Deficiency 4.22 (3.045-5.834) <.0001 
 Interaction Term 0.45 (0.334-0.598) <.0001 
 
I interpret these results as indicating that vitamin D deficiency and replacement are 
highly associated. It may be reasonable on a practical basis to consider models with 
vitamin D supplement as a predictor variable rather than the interaction term, for 
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simplicity or for generation of a risk scoring system, as this is more intuitive.  
However for this study, the interaction term will be included in final model 
development below along with main effects.  
Therefore vitamin D supplementation improved survival overall, and to a greater 
degree in deficient patients. The univariate overall risk of death was reduced for 
subjects on supplements with OR 0.62 (CI 0.469- 0.806), P = .0004. When both 
vitamin D deficiency and replacement were entered as predictor variables in a 
regression model, the OR for vitamin D deficiency was 3.12 (CI 2.250- 4.297) and 
the OR for vitamin supplements was 0.56 (CI 0.428- 0.737), both P’s < .0001. 
When added to the expanded regression model for death the vitamin D supplement 
OR was 0.43, P < .0001 (Table 9). Removal of age in the model did not significantly 
change the outcomes. When added to the disease state only regression model for 
death the vitamin D supplement OR was 0.44, P < .0001 (Table 10). Stepwise 
selection results are given in Table 11.  
Table 9 Logistic Regression for death with Vitamin D replacement added to expanded 
model 
Predictor OR CI P 
CAD 1.32 0.970-1.799 .0769 
Diabetes 1.71 1.254-2.326 .0007 
Cardiomyopathy 2.35 1.643-3.326 <.0001 
HTN 0.86 0.629-1.170 NS 
Vitamin D Supplement 0.43 0.313-0.587 <.0001 
Atrial Fibrillation 1.25 0.883-1.761 NS 
Age 1.02 1.008-1.033 .0012 
Gender (female) 0.64 0.480-0.861 .003 
BMI 0.96 0.936-0.981 .0003 
Creatinine 1.01 0.985-1.030 NS 
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Table 10 Logistic Regression with Vitamin D replacement added to disease state 
model: 
Predictor OR CI P 
CAD 2.45 1.852-3.245 <.0001 
Diabetes 1.67 1.281-2.172 .0001 
Cardiomyopathy 3.09 2.189-4.355 <.0001 
HTN 1.62 1.249-2.091 .0003 
Vitamin D Supplement 0.44 0.335-0.589 <.0001 
Atrial Fibrillation 2.13 1.543-2.929 <.0001 
 
Vitamin D replacement was associated with a significantly lower occurrence of death 
in the models above, suggesting a protective role. When added to the hazard model 
using survival method 1the vitamin D supplementation hazard ratio for death was 
0.40 (CI 0.335-0.576)  for subjects on replacement with P < .0001. Using survival 
method 2 the vitamin D supplementation odds ratio for death was .46 (CI 0.342- 
0.589) with P <.0001. 
Survival by vitamin D supplementation using method 1 is shown in Figure 10, which 
demonstrates that survival was improved by supplementation. Survival by vitamin D 
supplementation and deficiency was also studied, with overlap of the survival curves, 
but suggestion of important interaction between vitamin D deficiency and 
replacement (Figure 11).  Significant differences in survival were seen only for the 
vitamin D deficient patients. 
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Figure 10 Survival by Vitamin D supplementation 
 
 
Figure 11 Survival Curves by Vitamin D deficiency and replacement. Combined 
curves below. 
 
32 
 
Separate Surival Curves for Vitamin D deficient patients (top) and non deficient 
patients (bottom) by Vitamin D replacment with expanded scale. Patients on 
supplements represented by the red lines, those not on supplements represented by the 
black lines. Significant differences in survival are seen only for the deficient patients. 
 
 
33 
 
Vitamin D Supplementation: Interactions with Other Medications 
 
To assess whether use of any vitamin reduced the positive association of vitamin D 
replacement (or the negative association of vitamin D deficiency) with death, an 
expanded analysis including these factors was added to the model with significant 
clinical predictors as well as vitamin D deficiency as a dichotomous variable. The 
results are given in Table 12 and indicate that any use of vitamin supplement does not 
reduce the associations of vitamin D replacement or deficiency on mortality. The 
overall P was <.0001 with c = .772. 
Table 12 Logistic regression using stepwise selection with vitamin D replacement and 
any vitamin use added to model 
Predictor OR CI P 
CAD 2.37 1.784-3.140 <.0001 
Diabetes 1.44 1.106-1.881 .0069 
Cardiomyopathy 3.12 2.219-4.395 <.0001 
HTN 1.63 1.263-2.114 .0002 
Vitamin D Supplement 0.31 0.214-0.447 <.0001 
Gender (female) 0.49 0.392-0.621 <.0001 
Vitamin D Deficiency 2.87 2.061-4.005 <.0001 
Any Vitamin 1.54 1.123-2.101 .0072 
 
These relationships continued to be significant when statin and aspirin use were 
added to the regression model. This argues against the benefit of vitamin D 
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supplements being due primarily to associated use of other medications which have 
shown survival benefit in prior studies (Table 13). 
Table 13 Logistic regression using stepwise selection model with statin and aspirin 
use added to model. 
Predictor OR CI P 
CAD 3.06 2.215-4.226 <.0001 
Diabetes 1.61 1.222-2.113 .0007 
Cardiomyopathy 3.51 2.478-4.985 <.0001 
HTN 1.91 1.450-2.506 <.0001 
Vitamin D Supplement 0.45 0.339-0.602 <.0001 
Statin Use 0.41 0.296-0.556 <.0001 
Vitamin D Deficiency 2.68 1.923-3.735 <.0001 
Aspirin 1.43 1.063-1.924 .0182 
Gender (female) 0.49 0.390-0.620 <.0001 
 
 Vitamin D Deficiency and Supplementation: Final Model 
Extensive modeling was performed testing different combinations of parameters and 
using Hosmer and Lemeshow goodness-of-fit testing to develop a model which 
included important parameters without excess variables. A model which fulfilled 
these criteria and produced a goodness-of-fit statistic indicating adequacy of the 
model included vitamin D deficiency, gender, coronary artery disease, 
cardiomyopathy, vitamin D supplementation, and the Vitamin D 
deficiency*supplementation term.  Because of the significant interaction between 
35 
 
vitamin D deficiency and replacement separate analyses were done for the deficient 
and non deficient subjects. The details of the logistic regression model for death for 
the vitamin D deficient subjects are given in Table 14. Vitamin D supplementation is 
a significant negative predictor variable for death. Table 15 provides the model for 
the subjects not vitamin D deficient. Note that vitamin D supplements are not a 
significant predictor of death for these subjects. 
Table 14 Final Logistic Regression Model for Death (Vitamin D as dichotomous 
variable) for vitamin D deficient subjects. 
 
 
Model: 
 
Logit p(death) = -3.20 +  0.86(Coronary Artery Disease) + 1.17(Cardiomyopathy) – 
0.66(Gender/female) + 0.49(Diabetes) + 0.45(Hypertension) – 0.97(Vitamin D 
Supplement) 
 
Odds Ratio for Death = e-3.20  + 0.86(Coronary Artery Disease) + 1.17(Cardiomyopathy) – 
0.66(Gender/female)  +0.49(Diabetes) + 0.45(Hypertension)– 0.97(Vitamin D Supplement) 
P < .0001   
 
c = 0.745 
 
Variable OR P 
Diabetes 1.63 (1.229-2.162) 0.0007 
Coronary Artery Disease 2.37 (1.749-3.219) <.0001 
Cardiomyopathy 3.22 (2.218-4.662) <.0001 
Gender (female) 0.52 (0.402-0.658) <.0001 
Hypertension 1.57 (1.185-2.072) 0.0016 
Vitamin D Supplement 0.38 (0.280-0.519) <.0001 
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Table 15 Final Logistic Regression Model for Death (Vitamin D as dichotomous 
variable) for subjects not Vitamin D deficient. Vitamin D supplementation was not a 
significant predictor variable. 
 
 
Model: 
Logit p(death) = -4.41 +  1.10(Coronary Artery Disease) + 1.06(Cardiomyopathy) – 
0.93(Gender/female)  + 0.80(Hypertension) 
Odds Ratio for Death = e-4.41  + 1.10(Coronary Artery Disease) + 1.06(Cardiomyopathy) – 0.93(Gender/female)  + 
0.80(Hypertension) 
P < .0001 
c = 0.778 
 
Table 16 presents a final logistic regression model for death in the subjects not on 
vitamin D supplementation who are vitamin D deficient (as a dichotomous variable. 
For patients on vitamin D supplements vitamin D deficiency was not a significant 
predictor of death. 
 
 
 
Variable OR P 
Coronary Artery Disease 3.00 (1.447-6.201) 0.0031 
Cardiomyopathy 2.88 (1.209-6.841) 0.0169 
Gender (female) 0.40 (0.202-0.770) 0.0064 
Hypertension 2.23 (1.147-4.337) 0.0181 
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Table 16 Final Logistic regression model for death for subjects not on vitamin D 
supplements (for patients on supplements vitamin D deficiency was not a significant 
predictor of death). 
 
Variable OR P 
Vitamin D Deficiency (dichotomous) 3.51 (2.400-5.125) <.0001 
Coronary Artery Disease 2.99 (2.180-4.106) <.0001 
Cardiomyopathy 3.34 (2.234-4.994) <.0001 
Gender (female) 0.45 (0.344-0.579) <.0001 
Hypertension 1.87 (1.419-2.458) <.0001 
 
Model: 
Logit p(death) =  -  4.40 + 1.25(Vitamin D Deficiency) + 1.10(Coronary Artery 
Disease) + 1.21(Cardiomyopathy)  -  0.81(Gender/female)   + 0.62(Hypertension) 
Odds Ratio for Death = e-4.40 + 1.25(Vitamin D Deficiency) + 1.10(Coronary Artery 
Disease) + 1.21(Cardiomyopathy) – 0.81(Gender/female)  + 0.62(Hypertension) 
P < .0001 
c = 0.776 
 
Table 17 repeats the analysis presented in Table 17 including the continuous vitamin 
D level as a predictor variable for patients not on vitamin D supplements. Note the c 
value of .799. These models appear to have predictive value and are readily available 
clinical parameters which could be utilized in a risk assessment scale. 
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Table 17 Final Logistic regression model for death for subjects not on vitamin D 
supplements when vitamin D level as a continuous variable was included in the 
model (for patients on supplements vitamin D level was not a significant predictor of 
death). 
 
Variable OR P 
Vitamin D Level (continuous) 0.95 (0.934-0.958) <.0001 
Coronary Artery Disease 3.15 (2.289-4.331) <.0001 
Cardiomyopathy 3.37 (2.246-5.063) <.0001 
Gender (female) 0.46 (0.358-0.602) <.0001 
Hypertension 1.80 (1.365-2.373) <.0001 
 
Model: 
Logit p(death) =  -  2.29 – 0.06(Vitamin D Level) + 1.15(Coronary Artery Disease) + 
1.22(Cardiomyopathy)  -  0.77(Gender/female)   + 0.58 (Hypertension) 
Odds Ratio for Death = e-2.29 – 0.06(Vitamin D Level) + 1.15(Coronary Artery Disease) + 
1.22(Cardiomyopathy) – 0.77(Gender/female)  + 0.58(Hypertension) 
P < .0001 
 
Vitamin D Deficiency and Coronary Artery Disease Risk Factors  
To examine the relationship between BMI and vitamin D deficiency, linear regression 
with BMI as the predictor variable and vitamin D level (continuous) as the dependent 
variable showed a highly significant negative association (beta -0.3134, P < .0001). 
Therefore higher BMI was associated with lower vitamin D levels. Logistic 
regression with vitamin D deficiency as a dichotomous variable showed a similar 
association, with OR for BMI 1.057 (CI 1.046-1.068) (P < .0001), again confirming 
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increased risk of vitamin D deficiency with increasing BMI. These findings may 
explain one mechanism for the association between obesity and cardiovascular 
disease processes. 
The association between vitamin D level as a continuous predictor variable and LDL 
cholesterol measurement as the dependent variable was also examined. There was a 
significant negative association between vitamin D level and LDL value, with a beta 
of -0.1956, P = .0005). A similar analysis with HDL cholesterol as the dependent 
variable found a significant positive association between vitamin D level and HDL 
measurement (beta 0.1734, P < .0001). Likewise vitamin D levels were associated 
with triglyceride measurements. The beta was -1.126 with P < .0001). Thus for every 
increase of 1 unit of vitamin D, triglyceride levels dropped by over 1 unit. 
These analyses demonstrate significant associations between vitamin D levels and 
known risk factors for cardiac disease. 
Discussion: 
A number of cardiovascular disease states have been associated with vitamin D 
deficiency. A summary follows, arranged by disease process. 
Vitamin D and Hypertensive Vascular Disease 
Essential hypertension is a major risk factor for cardiovascular disease. Vitamin D 
appears to be related to blood pressure control via multiple pathways. Calcitriol levels 
are inversely related to serum renin activity 13. Similarly a drop in blood pressure was 
seen in subjects who were exposed to ultraviolet B radiation which converts vitamin 
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D to 25 [OH] vitamin D 14. The effects of calcitriol on suppression of renin activity 
are probably secondary to increased intracellular calcium levels 15,16. Vitamin D 
replacement in deficient subjects significantly improved flow mediated dilatation of 
the brachial artery suggesting the role of vitamin D in the sensitivity of vascular 
smooth muscle cells 17.  
Initial small retrospective observational studies have studied correlations between 
vitamin D levels and systolic blood pressure.18-20 In a small study from Belgium of 25 
patients with hypertension, 25 [OH] vitamin D levels were significantly inversely 
correlated with systolic blood pressure, diastolic blood pressure, and calf vascular 
resistance 18. In a subsequent study involving normotensive men, a similar inverse 
correlation between 1, 25 [OH]2 vitamin D and systolic blood pressure was observed 
19.  
A large cross-sectional national study involving a non-institutionalized population 
aged >20 years, the third National Health and Nutrition Examination Survey 
(NHANES III), was carried out in the United States between 1988–1994. This study 
population was used to evaluate the cross-sectional relationship between serum 25-
hydroxyvitamin D concentrations and blood pressure 21. After excluding those who 
were on antihypertensive medications, a total of 12,644 patients were included in the 
analysis. The mean blood pressure varied inversely with serum 25 [OH] vitamin D 
levels, with the association remaining significant after adjustment for age, sex, race-
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ethnicity, and physical activity. The impact of vitamin D deficiency in the elderly 
(age > 50 years) was highly significant (p=0.021) 21.  
Interventions with vitamin D replacement were attempted to support the hypothesis 
that changes in vitamin D status affect blood pressure. In a randomized study, women 
older than 70 years who had 25 [OH] D levels less than 20 ng/ml were randomly 
assigned to receive supplementation with calcium 1200 mg/day only or calcium 1200 
mg/day plus vitamin D (cholecalciferol) 800 IU/day. Within 8 weeks of treatment, the 
systolic blood pressure in the group treated with vitamin D dropped on an average of 
13mm of Hg (p=0.02) 22 . In a similar randomized study involving patients with 
diabetes mellitus and serum 25[OH] D levels less than 20 ng/ml, patients were 
randomly assigned to receive a one-time dose of ergocalciferol 100,000 IU or a 
placebo. Vitamin D supplementation produced a significant decrease in systolic blood 
pressure 23. Similar benefits of vitamin D on blood pressure were noticed in other 
small studies 14,20.  
Vitamin D and Peripheral Vascular Disease 
25[OH]D levels  were inversely correlated to calf vascular resistance and positively 
correlated with calf blood flow 18. Similar associations were identified in the 
NHANES study. After multivariable adjustment for demographics, co-morbidities, 
physical activity level, and laboratory measures, low 25[OH] vitamin D levels were 
associated with a higher prevalence of peripheral arterial disease 24. Vitamin D 
deficiency is also strongly associated with increased thickness of intima-media in 
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carotid arteries 25.  One-third of the excess risk of PAD in an African American 
population was attributed to racial differences in vitamin D status 26. Similarly, a high 
prevalence of vitamin D deficiency with secondary hyperparathyroidism was 
observed in a non-diabetic population with peripheral vascular disease 27. No 
interventional studies have been reported to identify the specific effect of vitamin D 
replacement on peripheral vascular disease to the present. 
Vitamin D and Diabetes Mellitus 
Diabetes mellitus is a major risk factor for coronary artery disease and a sign of a 
profound metabolic derangement. Pancreatic beta cell dysfunction, peripheral tissue 
resistance to insulin, and chronic inflammation appear to be the possible mechanisms 
for the role of vitamin D in the expression of diabetes mellitus 28. Vitamin D receptors 
have been found in pancreatic islets indicating the possible role for vitamin D in 
insulin secretion 29. Basal insulin secretion rate was not altered in VDR knockout 
mice30 but insulin secretion rate after a challenge with glucose diet was impaired in 
vitamin D deficiency 31. Vitamin D might affect intracellular calcium levels in 
pancreatic cells which is an important stimulus for insulin secretion. In the peripheral 
tissues, VDR was found in skeletal muscles and adipose tissue. Vitamin D also has 
been shown to control insulin receptor expression and insulin responsiveness for 
glucose transport 32, establishing its role in both insulin secretion and sensitivity. 
Observational human studies showed the seasonal variation 33 and geographical 
variation 34 of type 1 diabetes mellitus and its relationship to vitamin D deficiency. 
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The European Community sponsored Concerted Action on the Epidemiology and 
Prevention of Diabetes study found a 33% reduction in the risk of developing 
childhood-onset type-1 DM in children who received vitamin D supplementation 35. 
Seasonal variations of glycemic control attributed to vitamin D level fluctuations 
were reported 36. Replacing vitamin D improves insulin secretion and peripheral 
insulin sensitivity in type 2 diabetic patients 37,38 as well as HbA1C levels 39. 
Metabolic syndrome is also prevalent in patients with vitamin D deficiency 40. 
Although the data from observational studies is strong, expected benefit from 
replacement of vitamin D on fasting blood glucose, glucose tolerance, or insulin 
sensitivity has not been observed in all studies 41,42. The variance may be due to 
ethnic differences, VDR gene polymorphisms 43  or inadequate dosing regimens. 
Nevertheless, two meta-analyses pooling large amounts of data did show benefit with 
vitamin D replacement 29,44. 
Vitamin D and Lipid Metabolism 
Serum levels of 1, 25-(OH)2-vitamin D are inversely correlated to VLDL and 
triglyceride levels 45. Vitamin D deficiency may cause an abnormal lipid profile by 
increasing peripheral insulin resistance and by contributing to metabolic syndrome.  
Studies have suggested that statin therapy may increase vitamin D levels, a finding 
that may account for some of the non-lipid pleiotropic actions of statins 44-49. It is 
postulated that inhibition of HMG Co-A (3-hydroxy-3 methylglutaryl coenzyme A) 
reducatse enzyme by statins result in increased 7-dehydrocholesterol, a substrate for 
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the enzyme. This excess 7-dehydrocholesterol is then converted to 25-
hydroxycholecalciferol by sunlight or the CYP11A1 enzyme, thereby increasing 
vitamin D levels 47,49,50. In addition, a recent study looked at reduction in vitamin D 
receptor signaling in diabetics and found increased foam cell formation in 
macrophages, an early sign of atherosclerosis 51. 
Vitamin D and Coronary Artery Disease 
As discussed previously, hypertension, diabetes mellitus, and lipid levels are effected 
by vitamin D. Vitamin D has also been shown to effect endothelial function 17,22, and 
decrease vascular calcification 52. Calcification of coronary arteries was inversely 
correlated with vitamin D levels 53. Earlier observations in the 1980s and 1990s found 
geographic and seasonal differences in mortality from ischemic heart disease (IHD) 
45,54. The initial suggestion of vitamin D as a protective factor came from a study 
which showed mortality from IHD was inversely proportional to the hours of sunlight 
in the United Kingdom 45. 
Larger cross-sectional observations came from The National Health and Nutritional 
Examination Surveys (NHANES) conducted between 1988–1994 and 2000–2004. In 
the initial survey, a total of 16,603 men and women aged 18 years or older were 
studied. Participants with IHD and stroke had a greater frequency of 25[OH] D 
deficiency (p<0.0001) 55. This was confirmed by the recent study involving 8,351 
adults. The prevalence of vitamin D deficiency was 74% in patients with coronary 
artery disease and heart failure 56. The lowest quartile of 25[OH] vitamin D level 
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(<17.8 ng/mL) was independently associated with all-cause mortality in the general 
population 57. Together, the findings of these epidemiologic studies suggest that 
suboptimal vitamin D status is associated with poor cardiovascular outcomes. 
Multiple cohort studies evaluated the role of vitamin D prospectively in long-term 
cardiovascular outcomes in subjects with no history of cardiovascular disease. In 
renal dialysis patients, untreated vitamin D deficient subjects were at significantly 
increased risk for early mortality 58. Similarly, healthy male health professionals aged 
40 to 75 years with no history of coronary artery disease, vitamin D deficiency 
(25[OH]D <15 ng/mL) exhibited a 2-fold increased rate of myocardial infarction over 
10 year period 59. In the Framingham Offspring Study, subjects with no history of 
cardiovascular disease and severe vitamin D deficiency (25(OH)D <10 ng/mL) 
experienced a hazard ratio of 1.80 (95% CI, 1.05–3.08) for developing a first 
cardiovascular event after 5 years of follow-up compared with subjects with of 
25(OH)D levels of >15 ng/mL 60. In more than 3000 subjects undergoing coronary 
angiography, those with severe vitamin D deficiency (25(OH)D <10 ng/mL) had 3 to 
5 times the risk of death from sudden cardiac death, heart failure or fatal stroke during 
a 7-year follow-up period compared with those who had optimal levels of vitamin D 
(25(OH)D >30 ng/mL) 61,62.  
Although the significance of vitamin D deficiency in coronary artery disease is well 
established in observational studies, few studies have been conducted to evaluate the 
impact of vitamin D supplementation on the risk of cardiovascular mortality. In the 
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Women’s Health Initiative CAD trial, postmenopausal women were randomized to 
vitamin D 400 IU daily and 1000mg of calcium supplementation and were followed 
for 7 years. These supplements had no significant effect on mortality rates 63. Elderly 
individuals living in the community, aged between 65 to 85 years were given 100,000 
IU oral vitamin D3 (cholecalciferol) supplementation or matching placebo every four 
months over five years. After 5 years, the relative risk for total mortality did not 
change (Odds ratio 0.88, CI 0.74 to 1.06, P=0.18) 64. However neither of these studies 
provided what may be optimal daily doses of supplemental vitamin D. 
Vitamin D and Heart Failure 
Cardiomyocytes express vitamin D receptors 65. Histological examination of 
ventricular muscle from vitamin D deficient rats revealed a significant decrease in 
myofibrillar area and increase in extracellular space with collagen; and restoring 
normal calcium levels did not prevent the increase in myocardial collagen 66. 
Increased extracelluar space with collagen in the myocardium is associated with 
reduced ejection fraction and CHF. In mice, VDRs are closely associated with t-
tubule proteins and are ideally positioned to exert an immediate effect on signal 
transduction mediators and ion channels. VDR knockout mice developed an altered 
rate of relaxation and increased cardiomyocyte hypertrophy 65.  
The major potential mechanisms which may explain the direct protective effects of 
vitamin D against heart failure include:  effects on myocardial contractile function, 
regulation of natriuretic hormone secretion, effects on extracellular matrix 
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remodeling, reduced left ventricular hypertrophy, and the regulation of inflammatory 
cytokines 67.  Indirectly vitamin D can also affect heart function by altering 
parathyroid hormone and serum calcium levels. The initial evidence in humans came 
from dialysis patients. In uremic cardiomyopathy patients, treatment with 1 
microgram of 1, alpha-hydroxycholecalciferol daily for 6 weeks produced a decrease 
in plasma PTH concentration and an increase in fractional fiber shortening on M-
Mode echocardiogram (p < 0.025) 68.  
Observational studies showed that osteoporosis, osteopenia and low serum 25 [OH] 
vitamin D levels are common in congestive heart failure (CHF) patients 69. This may 
explain  in part the ethnic variance in the incidence of CHF and serum vitamin D 
levels 70. A case-control study demonstrated that CHF patients and controls differed 
in several vitamin D associated lifestyle factors such as urban dwelling, sports club 
membership and number of summer holidays during earlier periods of lives 52. In a 
study involving African American patients with left ventricular ejection fraction less 
than 35%, vitamin D deficiency (levels ≤ 30ng/mL) was associated with 
decompensated CHF and prolonged hospital stays 71. Low vitamin D levels were 
associated with poor outcomes in patients with end stage heart failure awaiting heart 
transplantation 72. A study on VDR gene polymorphisms in patients with end stage 
renal disease (ESRD) when compared to normal subjects suggested that vitamin D 
signaling is implicated in the regulation of left ventricular mass and hypertrophy in 
ESRD patients (p<0.001) 73. 
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Hemodialysis patients with secondary hyperparathyroidism when treated with IV 
calcitriol showed pronounced reductions in interventricular wall thickness (P = 0.01), 
left ventricular posterior wall thickness (P < 0.05), and left ventricle mass index (P < 
0.01) 74. Similarly vitamin D supplementation reduced the inflammatory markers in 
CHF patients and improved serum parathyroid hormone levels. However there was no 
significant direct survival benefit with vitamin D supplementation demonstrated in 
this study 75.  
Vitamin D and Arrhythmia 
Correction of vitamin D deficiency and hypocalcemia resulted in control of 
incessant ventricular tachycardia and cardiomyopathy in a recent report 76. A rare 
case of fetal atrial flutter was reported in vitamin D resistant rickets 77. In an animal 
study, rats fed a vitamin D deficient diet for 12 weeks developed significant 
shortening of QT interval despite normal serum calcium levels when compared to 
normal rats 78. Vitamin D deficiency can result in hypocalcemia and prolongation of 
QTc interval, but current evidence on vitamin D deficiency as an etiological factor for 
arrhythmia has not been established.  
Vitamin D and Mortality 
Several references already cited as well as additional studies and meta-analysis 
suggest that vitamin deficiency has a negative association with survival while 
supplementation decreases overall mortality.53,79-81 
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Limitations of the present study: 
This was a retrospective, observational trial with a selected population, introducing 
possible bias. The study population derived from patients who had their vitamin D 
levels measured in a hospital laboratory and who were patients in a cardiovascular 
practice and included in its electronic medical records. Extrapolation to other 
populations may not be appropriate. Isolated vitamin D measurement may not reflect 
long-term levels. We made an arbitrary decision to use the lowest vitamin D 
measurement for analysis as this value was felt to most likely represent the subjects’ 
baseline non supplemented level. We were unable to accurately associate the timing 
of vitamin D measurement and supplement initiation. Dose and duration of 
supplementation were not analyzed. Inclusion of vitamin D in multivitamin 
supplements (typically 400 IU per tablet) was not considered. Projection of 
recommendations for large scale supplementation awaits prospective, randomized 
trials. 
Summary 
In this retrospective cohort study of patients followed in a large cardiovascular 
practice at an academic medical center, with data obtained from electronic medical 
records; vitamin D deficiency was shown to be significantly positively associated 
with several cardiovascular outcomes and poorer survival, consistent with prior 
studies. Our data also shows an association of vitamin D supplementation with better 
survival. This association is stronger in vitamin D deficient subjects than in those who 
50 
 
are not deficient, suggesting an incremental benefit of vitamin D supplementation for 
patients who are deficient. This benefit is independent of use of other medications 
such as aspirin or statins. 
Conclusions 
Observational studies strongly associate vitamin D deficiency with a variety of 
cardiovascular diseases beyond defects in bone and calcium metabolism. Vitamin D 
has multiple associations and mechanisms which potentially may impact 
cardiovascular health (Figures 1 and 3)1-4,53,79-85. Our study shows a strong association 
of vitamin D deficiency with coronary artery disease, diabetes, cardiomyopathy, and 
death. When included in survival and hazard models with several disease states, 
vitamin D deficiency is a strong independent predictor of death. Several studies have 
reported on the association between obesity and low vitamin D levels82-85, which we 
also observed in our study population. As the prevalence of overweight status is 
increasing in the United States as well as many other developed and emerging 
nations, vitamin D deficiency may be increasingly common in the future. In addition 
our study showed an association between vitamin D deficiency and unfavorable 
serum lipid values. 
Since vitamin D deficiency is widespread, strategies directed at population based 
supplemental programs may prove beneficial.80 To date however, prospective studies 
evaluating vitamin D supplementations are few and have not consistently shown 
benefit. It is possible that the lack of benefit in these studies may have resulted from 
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suboptimal levels of vitamin D supplementation or other unknown factors. Many 
prior studies of vitamin D supplementation have employed doses of 400-800 IU, 
which may not be adequate to assure adequate serum levels, with more appropriate 
daily supplement doses suggested as 1000-2000 IU.80,86  Nevertheless, the growing 
body of observational data and consistent findings of relatively high rates of low 
vitamin D serum levels warrant further well designed studies to investigate the 
relationship between vitamin D and cardiovascular health. Our study shows a 
significant association of vitamin D supplement use and improved survival, 
supporting the potential benefit of active vitamin D replacement. 
Further investigation of these topics is warranted. Long-term prospective studies of 
various vitamin D dosage supplements in both healthy and diseased populations are 
indicated, as well as consideration of recommendations for supplementation in the 
general population while these studies are in progress. A recently announced 
prospective randomized study planning to enroll 20,000 elderly people will examine 
the potential cardiovascular benefits of vitamin D and omega-3 supplementation 87. It 
is anticipated that this study will answer many of the questions raised from the 
observational and smaller interventional studies on vitamin D and cardiovascular 
disease processes described in this paper, as well as our own analysis. 
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Appendix 1 
SAS Program: (sample code, multiple iterations were used for different aspects 
of the analysis) 
dm 'log;clear;output;clear;'; 
options ls=76 ps=88 ; 
data vitd; 
set storage.vitd; 
 
 
endofstudy2 = Today()- 30; 
endofstudy = 18187; 
 
if death = 1 then Survival =  DOD - BD; 
else Survival = endofstudy - BD; 
 
if death = 1 then Survival2 = DOD - COL_DATE; 
else Survival2 =  endofstudy - COL_DATE; 
 
proc univariate normal plot; var result; run; 
 
proc reg; model TRIGLYCER = RESULT;    run; 
 
 
/*proc lifetest plot = (S); 
time survival2*death(0); 
strata Ddef; 
run; 
 
proc lifetest plot = (S); 
time survival*death(0); 
strata Ddef; 
run; 
 
proc phreg; 
model survival*death(0) = cad diabetes ddef htn age bmi 
gender_recode/rl ties = exact; 
run; 
 
proc phreg; 
ddeftm=ddef*log(survival); 
CADtm=CAD*log(survival); 
model survival*death(0) = cad cadtm ddef ddeftm /rl ties = exact; 
proportionality_test: test ddeftm, cadtm; 
run; 
 
proc phreg; 
ddeftm=ddef*log(survival); 
CADtm=CAD*log(survival); 
model survival*death(0) = result vitamin_d interactd /rl ties = 
exact; 
proportionality_test: test interactd; 
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run; 
 
proc logistic descending; model death = ddef CAD HTN cardiomyo 
diabetes age BMI Cardia_EF creatinine gender_recode; run;  
 
proc logistic descending; model death = ddef CAD HTN cardiomyo 
diabetes age BMI Cardia_EF creatinine gender_recode / 
        selection=stepwise sle=0.1 sls=0.15 scale=none aggregate; 
run;  
 
proc freq; tables vitamin_d*ddef*death/CMH; run; 
 
proc freq; tables ddef*afib/CMH; run; 
 
proc logistic descending; model death = ddef vitamin_D CAD HTN 
cardiomyo diabetes age BMI Cardia_EF creatinine gender_recode; run;  
 
proc logistic descending; model death = ddef vitamin_D CAD HTN 
cardiomyo diabetes AFIB; run;  
 
proc phreg; 
model survival*death(0) = cad vitamin_d diabetes ddef htn age bmi 
gender_recode/rl ties = exact; 
run; 
 
proc phreg; 
model survival*death(0) = cad vitamin_d diabetes ddef htn cardiomyo 
afib/rl ties = exact; 
run; 
 
proc freq; tables vitamin_D*death/CMH; run;  
 
proc freq;                                                                                                          
tables DDEF*DEATH VITAMIN_D*DDEF*DEATH / MEASURES CHISQ AGREE CMH                                                                     
      NOPERCENT;                                                                                                                         
run;                                                                                                                                     
     
 
proc lifetest plot = (S); 
time survival*death(0); 
strata vitamin_d ddef; 
run; */ 
 
proc logistic descending;                                                                                                 
model DEATH = CAD DIABETES CARDIOMYO HTN VITAMIN_D / corrb covb;                                                                      
run;       
 
proc logistic descending;                                                                                                 
model DEATH = CAD DIABETES CARDIOMYO HTN VITAMIN_D AFIB AGE 
GENDER_RECODE                                                             
BMI CREATININE / selection=stepwise sle=0.1 sls=0.15 corrb covb;                                                                      
run;                                                                                                                                     
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proc reg; model result = BMI; run;  
 
 
/* dm 'log;clear;output;clear;'; 
options ls=76 ps=88 ; 
 
 
data vitd; 
set storage.vitd; 
 
 
endofstudy2 = Today()- 30; 
endofstudy = 18187; 
 
if death = 1 then Survival =  DOD - BD; 
else Survival = endofstudy - BD; 
 
if death = 1 then Survival2 = DOD - COL_DATE; 
else Survival2 =  endofstudy - COL_DATE; 
 
proc lifetest plot = (S); 
time survival2*death(0); 
strata Ddef; 
run; 
 
proc lifetest plot = (S); 
time survival*death(0); 
strata Ddef; 
run; 
 
proc contents data = vitd;  run;  
 
proc univariate plot normal; 
var age result; run; 
 
proc freq; 
tables G; run; 
 
proc univariate plot normal; 
var weight BMI cardia_ef; run; 
 
proc freq; 
tables ddef; run;  
 
proc freq; tables vitamin_d*ddef*osteopenia/CMH; run;  
 
proc logistic descending; model death = result; run; 
 
proc logistic descending; model death = ddef CAD HTN cardiomyo 
diabetes; run;  
 
proc logistic descending; model death = result CAD HTN cardiomyo 
diabetes; run; 
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proc logistic descending; model death = ddef CAD HTN cardiomyo 
diabetes age BMI Cardia_EF creatinine gender_recode; run;  
 
proc logistic descending; model DEATH = CAD DIABETES CARDIOMYO AGE 
BMI CARDIA_EF DDEF / 
        selection=stepwise sle=0.1 sls=0.15 scale=none aggregate; 
run;  
 
proc phreg; 
model survival2*death(0) = cad diabetes cardiomyo ddef age bmi 
cardia_EF/rl ties = exact; 
run;  
 
proc phreg; 
model survival2*death(0) = cad diabetes ddef htn age bmi/rl ties = 
exact; 
run; */ 
 
 
  *** Proportional Hazards Models *** ; 
  options pageno=1; 
  proc phreg data=STORAGE.vitd; 
     model SURVIVAL * DEATH (0) = DDEF AFIB CAD DIABETES CARDIOMYO 
HTN VHD 
     VITAMINANY VITAMIN_D A_INHIBITOR STATINS ASA GENDER_RECODE 
INTERACTB /RL ties = exact 
        selection= n;  strata vitamin_d; 
  run; 
 
  proc lifetest data=storage.vitd plot =(S); 
  time survival*death(0); 
  strata interactB ddef; 
  run; 
 
 
  proc lifetest data=storage.vitd plot =(S); 
  time survival*death(0); 
  strata ddef; 
  run; 
 
 *** Logistic Regression Analysis ***; 
  options pageno=1; 
  proc logistic data=STORAGE.vitd DESCEND; 
     model DEATH =   DDEF diabetes cardiomyo gender_recode  
       /ctable lackfit; 
  run; 
 
*** Logistic Regression Analysis ***; 
  options pageno=1; 
  proc logistic data=STORAGE.vitd DESCEND; 
     model DEATH =   ddef interactB diabetes cardiomyo gender_recode 
cad 
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       /ctable lackfit; 
  run; 
 
 
final model goodness of fit 
dm 'log;clear;output;clear;'; 
options ls=76 ps=88 ; 
 
 
data vitd; 
set storage.vitd; 
 
 
endofstudy2 = Today()- 30; 
endofstudy = 18187; 
 
if death = 1 then Survival =  DOD - BD; 
else Survival = endofstudy - BD; 
 
 
options pageno=1; 
  proc logistic data=STORAGE.vitd DESCEND; 
     model DEATH =   DDEF CAD cardiomyo gender_recode vitamin_D 
       /ctable lackfit; 
  run; 
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Appendix 2. Final model SAS output 
Final Model with Vitamin D as a dichotomous variable 
                                          11:48 Thursday, March 18, 2010   1 
 
                           The LOGISTIC Procedure 
 
                             Model Information 
 
          Data Set                      STORAGE.VITD 
          Response Variable             Death                Death 
          Number of Response Levels     2 
          Model                         binary logit 
          Optimization Technique        Fisher's scoring 
 
 
                  Number of Observations Read       10899 
                  Number of Observations Used       10899 
 
 
                              Response Profile 
 
                   Ordered                          Total 
                     Value     Death            Frequency 
 
                         1     1                      336 
                         2     0                    10563 
 
                     Probability modeled is Death='1'. 
 
 
                          Model Convergence Status 
 
               Convergence criterion (GCONV=1E-8) satisfied. 
 
 
                            Model Fit Statistics 
 
                                                Intercept 
                                 Intercept            and 
                   Criterion          Only     Covariates 
 
                   AIC            3001.633       2693.854 
                   SC             3008.930       2737.633 
                   -2 Log L       2999.633       2681.854 
 
 
                  Testing Global Null Hypothesis: BETA=0 
 
          Test                 Chi-Square       DF     Pr > ChiSq 
 
          Likelihood Ratio       317.7791        5         <.0001 
          Score                  439.9622        5         <.0001 
          Wald                   333.4625        5         <.0001 
 
 
                 Analysis of Maximum Likelihood Estimates 
 
                                     Standard          Wald 
  Parameter        DF    Estimate       Error    Chi-Square    Pr > ChiSq 
 
  Intercept         1     -4.0427      0.1764      525.1706        <.0001 
  Ddef              1      1.0915      0.1677       42.3572        <.0001 
  CAD               1      1.2081      0.1370       77.7529        <.0001 
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  CARDIOMYO         1      1.2325      0.1760       49.0589        <.0001 
  Gender_recode     1     -0.7283      0.1175       38.4141        <.0001 
  VITAMIN_D         1     -0.7584      0.1448       27.4458        <.0001 
 
 
                           Odds Ratio Estimates 
 
                                 Point          95% Wald 
             Effect           Estimate      Confidence Limits 
 
             Ddef                2.979       2.144       4.138 
             CAD                 3.347       2.559       4.378 
             CARDIOMYO           3.430       2.429       4.842 
             Gender_recode       0.483       0.383       0.608 
             VITAMIN_D           0.468       0.353       0.622 
 
 
       Association of Predicted Probabilities and Observed Responses 
 
            Percent Concordant       68.9    Somers' D    0.492 
            Percent Discordant       19.7    Gamma        0.556 
            Percent Tied             11.5    Tau-a        0.029 
            Pairs                 3549168    c            0.746 
 
                           The LOGISTIC Procedure 
 
                 Partition for the Hosmer and Lemeshow Test 
 
                                  Death = 1               Death = 0 
       Group       Total    Observed    Expected    Observed    Expected 
 
           1         596           5        2.62         591      593.38 
           2        1802           8       15.14        1794     1786.86 
           3        1561          22       18.24        1539     1542.76 
           4         943          23       18.92         920      924.08 
           5        3228          71       79.45        3157     3148.55 
           6         361          14       12.12         347      348.88 
           7        1494          76       74.22        1418     1419.78 
           8         914         117      115.30         797      798.70 
 
 
                  Hosmer and Lemeshow Goodness-of-Fit Test 
 
                     Chi-Square       DF     Pr > ChiSq 
 
                         8.5599        6         0.1999 
 
 
                            Classification Table 
 
            Correct      Incorrect                Percentages 
   Prob          Non-          Non-           Sensi-  Speci-  False  False 
  Level  Event  Event  Event  Event  Correct  tivity  ficity   POS    NEG 
 
  0.000    336      0  10563      0      3.1   100.0     0.0   96.9     . 
  0.020    290   4435   6128     46     43.4    86.3    42.0   95.5    1.0 
  0.040    193   8346   2217    143     78.3    57.4    79.0   92.0    1.7 
  0.060    111   9865    698    225     91.5    33.0    93.4   86.3    2.2 
  0.080     81  10204    359    255     94.4    24.1    96.6   81.6    2.4 
  0.100     77  10226    337    259     94.5    22.9    96.8   81.4    2.5 
  0.120     73  10259    304    263     94.8    21.7    97.1   80.6    2.5 
  0.140     73  10259    304    263     94.8    21.7    97.1   80.6    2.5 
  0.160     34  10454    109    302     96.2    10.1    99.0   76.2    2.8 
  0.180     31  10474     89    305     96.4     9.2    99.2   74.2    2.8 
  0.200     31  10474     89    305     96.4     9.2    99.2   74.2    2.8 
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  0.220     22  10474     89    314     96.3     6.5    99.2   80.2    2.9 
  0.240     22  10527     36    314     96.8     6.5    99.7   62.1    2.9 
  0.260     22  10527     36    314     96.8     6.5    99.7   62.1    2.9 
  0.280     22  10527     36    314     96.8     6.5    99.7   62.1    2.9 
  0.300     22  10527     36    314     96.8     6.5    99.7   62.1    2.9 
  0.320     22  10527     36    314     96.8     6.5    99.7   62.1    2.9 
  0.340     22  10527     36    314     96.8     6.5    99.7   62.1    2.9 
  0.360     22  10527     36    314     96.8     6.5    99.7   62.1    2.9 
  0.380      0  10563      0    336     96.9     0.0   100.0     .     3.1 
 
Vitamin D in final model as a continuous variable 
                              Model Information 
 
                     Data Set                      STORAGE.VITD 
                     Response Variable             Death                Death 
                     Number of Response Levels     2 
                     Model                         binary logit 
                     Optimization Technique        Fisher's scoring 
 
 
                              Number of Observations Read       10899 
                              Number of Observations Used       10899 
 
 
                                          Response Profile 
 
                               Ordered                          Total 
                                 Value     Death            Frequency 
 
                                     1     1                      336 
                                     2     0                    10563 
 
                                 Probability modeled is Death='1'. 
 
 
                                     Model Convergence Status 
 
                          Convergence criterion (GCONV=1E-8) satisfied. 
 
 
                          Deviance and Pearson Goodness-of-Fit Statistics 
 
                   Criterion          Value       DF     Value/DF     Pr > ChiSq 
 
                   Deviance       1435.6946     2858       0.5023         1.0000 
                   Pearson        4016.1785     2858       1.4052         <.0001 
 
                                  Number of unique profiles: 2864 
 
 
                                       Model Fit Statistics 
 
                                                           Intercept 
                                            Intercept            and 
                              Criterion          Only     Covariates 
 
                              AIC            3001.633       2663.880 
                              SC             3008.930       2707.658 
                              -2 Log L       2999.633       2651.880 
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                                      The LOGISTIC Procedure 
 
                              Testing Global Null Hypothesis: BETA=0 
 
                      Test                 Chi-Square       DF     Pr > ChiSq 
 
                      Likelihood Ratio       347.7538        5         <.0001 
                      Score                  461.2933        5         <.0001 
                      Wald                   352.1680        5         <.0001 
 
 
                             Analysis of Maximum Likelihood Estimates 
 
                                                 Standard          Wald 
              Parameter        DF    Estimate       Error    Chi-Square    Pr > ChiSq 
 
              Intercept         1     -2.2358      0.1354      272.7708        <.0001 
              result            1     -0.0463     0.00552       70.4926        <.0001 
              CAD               1      1.2353      0.1368       81.4861        <.0001 
              CARDIOMYO         1      1.2304      0.1764       48.6520        <.0001 
              VITAMIN_D         1     -0.7465      0.1449       26.5494        <.0001 
              Gender_recode     1     -0.7058      0.1174       36.1435        <.0001 
 
 
                                       Odds Ratio Estimates 
 
                                             Point          95% Wald 
                         Effect           Estimate      Confidence Limits 
 
                         result              0.955       0.944       0.965 
                         CAD                 3.439       2.630       4.497 
                         CARDIOMYO           3.423       2.422       4.836 
                         VITAMIN_D           0.474       0.357       0.630 
                         Gender_recode       0.494       0.392       0.621 
 
 
                   Association of Predicted Probabilities and Observed Responses 
 
                        Percent Concordant       75.6    Somers' D    0.533 
                        Percent Discordant       22.3    Gamma        0.544 
                        Percent Tied              2.0    Tau-a        0.032 
                        Pairs                 3549168    c            0.766 
 
 
                                                                  
                                      The LOGISTIC Procedure 
 
                            Partition for the Hosmer and Lemeshow Test 
 
                                             Death = 1               Death = 0 
                  Group       Total    Observed    Expected    Observed    Expected 
 
                      1        1092           9        5.02        1083     1086.98 
                      2        1088           7        8.85        1081     1079.15 
                      3        1092          11       11.83        1081     1080.17 
                      4        1090           8       14.91        1082     1075.09 
                      5        1087          19       18.46        1068     1068.54 
                      6        1087          18       23.23        1069     1063.77 
                      7        1092          30       30.03        1062     1061.97 
                      8        1090          47       38.08        1043     1051.92 
                      9        1091          53       53.96        1038     1037.04 
                     10        1090         134      131.64         956      958.36 
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                             Hosmer and Lemeshow Goodness-of-Fit Test 
 
                                Chi-Square       DF     Pr > ChiSq 
 
                                   10.3286        8         0.2427 
 
